Trials / Completed
CompletedNCT01895764
Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- University Hospital, Tours · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if association of methotrexate with adalimumab leads to decrease immunogenicity beside adalimumab alone in Ankylosing Spondylitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab | adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26 |
| DRUG | Methotrexate | methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26 |
Timeline
- Start date
- 2013-03-20
- Primary completion
- 2015-04-27
- Completion
- 2015-04-27
- First posted
- 2013-07-10
- Last updated
- 2026-04-03
Locations
11 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01895764. Inclusion in this directory is not an endorsement.